Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Soficitinib [inn]
2. Wqe4ath4kc
3. Schembl22856037
4. Gtpl14068
5. Compound 20 [wo2020259584]
6. (3as,6ar)-5-[5-chloro-2-[(1-methyl-1h-pyrazol-4-yl)amino]-4-pyrimidinyl]hexahydro-3a-methyl-beta-oxopyrrolo[3,4-c]pyrrole-2(1h)-propanenitrile
7. 2574524-67-5
8. 3-[(3as,6ar)-2-[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3a-methyl-3,4,6,6a-tetrahydro-1h-pyrrolo[3,4-c]pyrrol-5-yl]-3-oxopropanenitrile
9. Pyrrolo[3,4-c]pyrrole-2(1h)-propanenitrile, 5-[5-chloro-2-[(1-methyl-1h-pyrazol-4-yl)amino]-4-pyrimidinyl]hexahydro-3a-methyl-beta-oxo-, (3as,6ar)-
| Molecular Weight | 400.9 g/mol |
|---|---|
| Molecular Formula | C18H21ClN8O |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 103 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 655 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
75
PharmaCompass offers a list of Soficitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Soficitinib manufacturer or Soficitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Soficitinib manufacturer or Soficitinib supplier.
A Soficitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Soficitinib, including repackagers and relabelers. The FDA regulates Soficitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Soficitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Soficitinib supplier is an individual or a company that provides Soficitinib active pharmaceutical ingredient (API) or Soficitinib finished formulations upon request. The Soficitinib suppliers may include Soficitinib API manufacturers, exporters, distributors and traders.
Soficitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Soficitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Soficitinib GMP manufacturer or Soficitinib GMP API supplier for your needs.
A Soficitinib CoA (Certificate of Analysis) is a formal document that attests to Soficitinib's compliance with Soficitinib specifications and serves as a tool for batch-level quality control.
Soficitinib CoA mostly includes findings from lab analyses of a specific batch. For each Soficitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Soficitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Soficitinib EP), Soficitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Soficitinib USP).
